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Sipuleucel-T, an autologous cellular immunotherapy, was approved 
in April 2010 by the US Food and Drug Administration (FDA) for 
the treatment of patients with castration-resistant prostate cancer. 
In July 2010, Kantoff et al. (1) reported the results of the phase III 
trial (IMPACT), which was central to the FDA’s approval, and also 
underpins the pending application for approval with the European 
Medicines Agency. Both the accompanying editorial (2) and the 
FDA reviewers noted the lack of supportive evidence for the mech-
anism  proposed  by  sipuleucel-T’s  manufacturer  (Figure  1  and 
Table 1). The absence of such supportive data has raised the con-
cern that the 4.1-month survival benefit could be the result of a flaw 
in the trial design or from the chance imbalance of unmeasured 
prognostic variables.
We have reconsidered these trial results in light of unpublished 
data obtained from internal FDA documents that became available 
only after the approval of sipuleucel-T. We believe that analysis of 
the data in their totality challenges the published interpretation of 
the trial results and suggests a different conclusion about the effi-
cacy, and potentially safety, of sipuleucel-T. Because these data 
have not been debated publicly, we hope that this commentary will 
stimulate consideration of their implications.
New Observations From Previously 
Unpublished Data
Observation  1:  Two  Unexpected  Interactions  Between 
Patient Age and Survival
The most striking observation from the new data was an unexpected 
11-month difference in median survival between placebo patients 
younger than age 65 years and patients older than age 65 years 
(28.2 vs 17.2 months, respectively) (Table 2). Age is not normally 
prognostic for survival in castration-resistant prostate cancer patients 
receiving  chemotherapy  (7–9),  as  illustrated  by  the  17.6-month 
median survival for the 504 patients younger than 68 years vs the 
18.1-month survival for the 502 patients aged 69 years or older in 
the pivotal TAX 327 trial (10). Although post hoc subgroup analyses 
should be interpreted with caution, it is still noteworthy that the 
age  dependence  of  overall  survival  (OS)  in  the  placebo  arm 
(two-sided P < .001) is stronger than the treatment effect itself 
(Table 2).
Also, it could be observed for the first time in the unpublished 
data from the FDA that among the IMPACT patients younger than 
65 years, sipuleucel-T treatment appeared to have no effect on 
survival (hazard ratio of death = 1.41, 95% confidence interval = 0.87 
to 2.29), in contrast with patients 65 years or older (hazard ratio of 
death = 0.58, 95% confidence interval = 0.43 to 0.76) (11). This 
observation suggests that the overall results were driven entirely by 
the differential survival in older patients. This is counterintuitive 
given that standard vaccination strategies (12,13), and immunother-
apies in particular (14,15), are consistently less effective in the elderly 
and  therefore  raises  further  questions  concerning  the  immune   
enhancement mechanism proposed for sipuleucel-T. In addition, it 
appears remarkable that the younger patients for whom the inter-
vention did not appear to be effective lived longer (median = 29.0 
months) than the older patients for whom the intervention did 
appear to be effective (median = 23.4 months).
These  observations  from  the  unpublished  data  from  the   
sipuleucel-T  studies  generated  the  hypothesis  that  the  placebo   
intervention  might  have  had  a  clinically  significant  age-related 
impact on OS and should be further investigated to assess whether 
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it might have unintentionally introduced this active non-placebo 
effect. In the sipuleucel-T arm, the 5.6-month longer survival of 
the younger group, although less statistically significant, is also 
unexpected and should be tested against alternative interpretations 
of the trial results.
Observation 2: Older Patients in the Placebo Group 
Appear to Have Shorter OS Than Might Be Expected From 
Other Studies
To test the hypothesis that the placebo intervention had an age-
dependent effect on OS, we sought placebo groups from other 
trials with which their survival might be compared. In the original 
publication of the IMPACT trial results, Kantoff et al. (1) state, 
“The 21.7-month median survival of patients in the placebo group 
compares favorably with that in control groups in other random-
ized  trials  involving  similar  patient  populations  (range,  15.5  to   
21.7 months) (9,16–21), indicating that the treatment effect cannot 
be attributed to a poor outcome in the placebo group.” However, 
the control groups in the seven cited trials were not appropriate 
comparators for the IMPACT placebo group (Table 3). The initial 
IMPACT enrollment criteria selected asymptomatic patients with 
an Eastern Cooperative Oncology Group performance status of   
0 or 1, Gleason score of 7 or lower, and no visceral metastases. 
Each of these restrictions is associated with improved OS in mul-
tivariable predictive models developed by both Halabi et al. (7) and 
Armstrong  et  al.  (8).  After  40%  of  patients  had  already  been 
enrolled,  the  Gleason  restriction  was  removed  and  minimally 
symptomatic patients were accepted. The placebo groups cited by 
Kantoff et al. (1) did not share these restrictions and might there-
fore have been anticipated to have a shorter survival than that of 
the IMPACT placebo group. An illustration of how the multiple 
enrollment restrictions in IMPACT selected for a favorable prog-
nosis  is  seen  in  the  21.2-month  Halabi-predicted  survival  of  its 
placebo group vs 16 months for the placebo group in the cited 
Figure  1.  The  manufacturing  process  and  proposed  mechanism  for 
sipuleucel-T  (3).  A)  The  manufacturing  process  for  sipuleucel-T  is 
depicted. Mononuclear cells are harvested from the patient and shipped 
to the manufacturing facility (approximately 46% T cells, 7% B cells, 13% 
natural killer cells, and 25% monocytes) (4) on day 1. On days 2–3, cells 
are put through two buoyant density centrifugation steps before incuba-
tion  for  36–48  hours  with  a  chimeric  antigen  (PA2024),  consisting  of 
granulocyte-macrophage colony-stimulating factor (GM-CSF) to activate 
antigen presentation, which is linked to the prostatic acid phosphatase 
(PAP) tumor-associated antigen. Cells are given a final wash on days 3–4 
before shipment back to the clinic for reinfusion into the patient. This 
process is repeated every 2 weeks for a complete course of three cycles. 
B) The proposed mechanism for sipuleucel-T antitumor activity is given. 
The manufacturer proposes that during incubation on days 2–3, antigen-
presenting  cells  (APCs)  process  and  present  the  synthetic  antigen 
PA2024 on their surface, thereby becoming activated. Upon reinfusion, 
these  cells  are  hypothesized  to  activate  endogenous  T-cells,  thereby 
stimulating them to attack PAP-bearing prostate cancer cells.jnci.oxfordjournals.org    JNCI | Commentary 275
Table 1. Areas of concern regarding support for observed survival benefit of sipuleucel-T for castration-resistant prostate cancer*
Concern Public expressions of concern Source
Improvement in overall survival came without  
  evidence of a measurable antitumor effect
“Study group assignment had no significant effect on the time to tumor  
  progression.”
(2)
“1 of 341 patients in the sipuleucel-T group had a partial tumor response, and  
  3% had a reduction of at least 50% in PSA . . .Thus, the improvement in  
  survival came without evidence of a measurable antitumor effect.”
(2)
“It is hard to understand how the natural history of a cancer can be affected without  
  some apparent measurable change in the tumor, either evidence of tumor  
  shrinkage or at least disease stabilization reflected in a delay in tumor progression.”
(2)
Observations predicted by the proposed  
  mechanism of sipuleucel-T have not been  
  made. The absence of alternative  
  mechanisms leaves the 4.1-month survival  
  benefit without mechanistic underpinning
“It is not clear that Dendreon has put a high priority on measuring the immune  
  response in patients in their trials. Considering that there appears to be very  
  little tumor- and antigen-specific immune response in the vaccinated patient,  
  one would think that this would be a high priority.”
(5)
  T-cell proliferative responses to the chimeric 
    antigen (PA2024) did not translate to  
    responses to physiologic, human PAP
“The fact that they are able to get a response to PA2024 but consistently  
  not to PAP tumor antigen is troubling.”
“It was asked if they had any evidence of a specific response to human PAP.  
  They stated that, no, they do not yet have any evidence.”
(5)
  T-cell proliferative response to the  
    chimeric antigen (PA2024) or human PAP 
    did not correlate with improved survival
“No survival difference could be detected between patients in the  
  sipuleucel-T group who had T-cell proliferation responses to PA2024 or  
  prostatic acid phosphatase at week 6 and those who did not.”
(1)
*  PAP = prostatic acid phosphatase; PSA = prostate-specific antigen.
Table 2. Subgroup analysis by age of overall survival of patients 
in the phase III trials of sipuleucel-T for castration-resistant  
prostate cancer (6)*
Patient 
age, y
Sipuleucel-T Placebo
No. of 
patients
Median survival 
(95% CI), mo
No. of 
patients
Median survival 
(95% CI), mo
<65 106 29.0 (22.8 to 34.2) 66 28.2 (23.4 to 32.5)
≥65 382 23.4 (22.0 to 27.1) 183 17.3 (13.5 to 21.4)
*  CI = confidence interval.
GVAX trial (18). In fact, this predicted 5.2-month survival advan-
tage was not realized because the placebo groups from both of these 
two trials lived for a median of 21.7 months.
To find a placebo group with similar baseline characteristics to 
those of the IMPACT placebo group, we searched both published 
literature and abstracts. We did not find any other castration-resistant 
prostate  cancer  trials  with  similarly  restrictive  enrollment  criteria. 
However, we identified two subanalyses of larger trials that might 
provide  more  appropriate  populations  to  which  the  IMPACT   
placebo group may be compared. 1) In the aforementioned GVAX 
trial, Higano et al. (18) reported a subanalysis of the 264 men with 
the best baseline prognosis. For men with a Halabi-predicted sur-
vival greater than 18 months at enrollment, median survival was 
29.7 months on GVAX and 27.1 months in the placebo group. 
Because approximately 86% of patients in the IMPACT placebo 
group had an Halabi-predicted survival greater than 16 months 
(23),  the  28.2-month median survival of pooled placebo patients 
younger than 65 is in the range that might be anticipated for the 
entire IMPACT placebo group. 2) Berthold et al. (24) conducted a 
retrospective sub-analysis of the 110 minimally symptomatic patients 
from the TAX 327 study; a group similar to, though still not as highly 
selected for good prognosis, the IMPACT population. Men with 
minimal symptoms had prolonged survival (median = 25.6 months) 
compared with symptomatic patients (median = 17.1 months, P = .009). 
Furthermore,  the  median  survival  for  minimally  symptomatic 
patients in the group given docetaxel every 3 weeks (the chemo-
therapy  regimen  received  by  most  of  the  IMPACT  placebo 
patients) was 28.4 months. This comparison too suggests that the 
28.2-month median survival of the patients younger than 65 years 
in the sipuleucel-T trials is in the range of what should have been 
expected for all patients, regardless of age.
These  comparisons  with  OS  in  other  CPRC  trials  support   
the hypothesis that the “placebo” intervention might have had a 
clinically significant adverse impact on OS in older patients. This 
observation too calls for scrutiny of the placebo intervention, to 
assess whether it might unintentionally have introduced this effect.
Observation 3: Potential Harm From the IMPACT Study 
Interventions
To better understand the potential for harm from the study inter-
ventions,  we  sought  data  regarding  the  cellular  manipulation  in 
IMPACT.  Kantoff  et  al.  (1)  reported  no  specific  cell-level  data, 
which might be appropriate for a trial investigating the collection 
and manipulation of immune cells. Comparison of the cell counts 
performed on 526 lots of patient cells received from apheresis cen-
ters during an earlier phase III study (9901) (4,25) to the baseline 
circulating white blood cell measurements (11) shows that the “stan-
dard leukapheresis processing 1.5–2.0 times the patient’s estimated 
blood volume” removed more than 90% (median) of the patients’ 
circulating mononuclear cells. Cells in each lot were counted twice 
between steps in the manufacture of sipuleucel-T and underwent a 
final count before shipment for reinfusion into patients. Such data 
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Table 3. Comparison of the IMPACT placebo group with placebo groups cited by Kantoff et al. (1)*
Study
No of  
patients
Median  
OS for 
placebo, mo
Reasons why cited placebo group would be  
expected to have shorter OS compared with  
the IMPACT placebo group Study funding source(s)
Zoledronic acid (16) 208 15.5 The study did not restrict enrollment to minimal or absent  
  symptomatology. Among patients, 73% had baseline  
  pain vs 47% in IMPACT. The study conducted before  
  TAX 327 demonstrated a 2.9-month survival benefit  
  for docetaxel, leading to its approval by the FDA  
  in the year 2004
Novartis Pharmaceuticals  
  Corporation (now Novartis   
  International AG)
Docetaxel  
  (TAX 327) (10,17)
335 19.2 The study did not restrict enrollment to minimal or absent  
  symptomatology, and 45% of patients had clinically  
  significant baseline pain vs 0% in IMPACT. Baseline  
  visceral metastases was present in 22% of patients  
  vs 0% in IMPACT. Clinically significantly worse  
  baseline performance status and Gleason scores  
  than IMPACT patients
Aventis (now Sanofi S.A.)
Atrasentan (19) 401 20.3 The study excluded patients requiring opiate analgesia but,  
  unlike IMPACT, did not enroll 40% of patients under  
  explicit exclusion of all pain and with favorable Gleason  
  scores. No eligibility restrictions on patients with visceral  
  metastases were given. Enrolled from June 2001 to  
  September 2002, before TAX 327 demonstrated a  
  2.9-month survival benefit for docetaxel, leading to  
  its approval by the FDA. The study was conducted  
  at 180 sites in 21 countries, with variable local  
  supportive care practices, which could induce bias  
  in either direction
Abbott Laboratories
ZD4054 phase II (20) 107 17.3 The study excluded patients requiring opiate analgesia,  
  but unlike IMPACT, did not impose eligibility restrictions  
  on ECOG status, visceral metastases, pain, and Gleason  
  score. The study was conducted at 65 centers (of which  
  only 12 were in North America) across four continents  
  where placebo patients were given “best supportive  
  care according to local practice,” which could induce  
  bias in either direction
Astrazeneca PLC
Mitoxantrone (21)     Kantoff et al. (1) chose the arm receiving the low-dose 
  prednisone (median OS = 19 months) for comparison,  
  yet the mitoxantrone plus low-dose prednisone  
  (median OS = 23 months) would represent a more  
  appropriate comparator for the IMPACT placebo  
  group in which 50.3% of patients received docetaxel  
  and 8% received other chemotherapy. The IMPACT  
  placebo group excluded patients with visceral  
  metastases [6% of mitoxantrone group in the study  
  by Berry et al. (21)] and enrolled 75.4% of patients 
  with favorable Gleason scores. Patients were enrolled  
  from March 1997 to Jan 1999, and the results were  
  reported in the year 2001, before docetaxel was granted  
  FDA approval
Immunex Corporation  
  (now Amgen Inc)   Mitoxantrone plus  
    prednisone arm
56 23
  Prednisone  
    alone arm
63 19
PROSTVAC 
    phase II (9)
40 16.6 Post-treatment chemotherapy usage was neither prescribed  
  nor monitored. Results reported for the 40 placebo  
  patients are problematic for the many reasons  
  outlined by Small and Fong (22)
BN Immunotherapeutics  
  (now Bavarian Nordic)
GVAX (18) ~310† 21.7 Exclusion of opiate pain medication was the only enrollment  
  criterion used to select for a favorable prognosis
Cell Genesys (now BioSante   
  Pharmaceuticals Inc)
*  FDA = US Food and Drug Administration; OS = overall survival.
†  There is an approximate number of participants given for this trial because full results have not been published. The study completed accrual of 626 patients in 
the year 2007, randomized 1:1 between study arms, and all patients completed the initial 6-month treatment period.
than 65% (median) of the cells harvested from patients were lost at 
the  manufacturing  facility  during  the  two  centrifugation  steps   
performed on incoming cell lots and during the final cell wash (4). 
A  more  complete  description  of  the  sipuleucel-T  intervention 
would therefore include the extraction of more than 90% of circu-
lating mononuclear cells followed by the return of less than 35% 
of these cells 2 days later after incubation with chimeric antigen. 
This intervention is repeated three times at 2-week intervals.
Of particular note, the interventions administered to the placebo 
group  differed  from  those  in  the  sipuleucel-T  group  in  three jnci.oxfordjournals.org    JNCI | Commentary 277
Box 1. Select aged-related impairments of the immune 
system 
Decreased thymic production of naive T cells (27,28)
Collapse in diversity of both naïve and memory T cell subcom-
partments (13,29,30)
Decreased T-cell responsiveness resulting from both decreased 
expression of CD28 and proliferative exhaustion (14,31,32)
Increased  numbers  of  circulating  natural  killer  cells  with 
reduced responsiveness and cytotoxicity per cell (33)
Impaired  differentiation  of  CD34-positive  cells  into  mature 
dendritic cells (34)
Decreased  frequency  of  myeloid  peripheral  blood  dendritic 
cells (35)
Disruptions in T-cell/B-cell interactions (36)
Alterations in immune cell trafficking as a consequence of wide-
spread changes in cytokine and chemokine signaling (37–39)
important respects. 1) After the two centrifugations that begin the 
manufacturing process, two-thirds of the cells in each placebo lot were 
removed and frozen for possible later use, leaving only one-third of 
the cells for further processing and reinfusion into placebo patients. 
Thus, given the greater than 65% (median) of cells lost in processing 
and the further two-thirds removed for freezing, less than 12% of 
the original pheresed cell load was left for reinfusion into the placebo 
patients. 2) Also, cells processed into sipuleucel-T were incubated 
with the granulocyte-macrophage colony-stimulating factor/prostatic 
acid phosphatase (GM-CSF/PAP) chimeric protein, whereas cells 
processed  into  placebo  were  stored  in  medium  containing  no 
GM-CSF. GM-CSF is a cytokine that functions as a white blood cell 
growth factor, and furthermore, may have antitumor activity as a 
single agent in prostate cancer (26). 3) Whereas cells being processed 
into sipuleucel-T were incubated at 37°C for 36–44 hours, placebo 
cells were stored at 2°C–8°C. In our experience, storage of isolated 
mononuclear cells at 2°C–8°C for 36–44 hours can result in the death 
of most, if not all, of those cells. Neither the article by Kantoff et al. 
(1) nor the FDA review documents for sipuleucel-T specify a deter-
mination of the viability of placebo cells before reinfusion into the 
patient. Thus, at best, at each of the three interventions, placebo 
patients received less than 12% of their harvested cells back; and at 
worst, they received an infusion with an equivalent number of dead 
cells. These three differences between the placebo and experimental 
interventions were assumed to be benign and have no impact on OS 
in this population. However, this assumption remains to be proven, 
and the term “placebo” is inappropriate. The IMPACT placebo con-
stituted a biologically significantly different intervention that could 
have had distinct clinical properties and was therefore an inappro-
priate control for sipuleucel-T.
Synthesis and Discussion of Observations
The observations above suggest a simple, albeit unproven, alterna-
tive explanation of the IMPACT trial outcome. According to this 
alternative explanation, the enrollment criteria selected for a patient 
population  with  a  favorable  prognosis  of  approximately  28–29 
months and the placebo intervention, involving a repeated deple-
tion of circulating mononuclear cells, exerted an age-dependent 
adverse impact on OS. There are several possible explanations for 
this. Most simply, patients younger than 65 years may have been 
able to replace the lost cells (and clear the dead cells) with few or   
no negative consequences, as reflected in their 28.2-month survival 
(6). However, patients older than 65 years may have been harmed 
by the cell loss (or the infusion of dead cells), as reflected in their 
17.3-month survival, which is 11 months shorter than might have 
been predicted without the placebo intervention. It is noteworthy 
that  the  sipuleucel-T  intervention,  involving  a  similar,  though 
smaller,  repeated  depletion  of  circulating  lymphocytes,  may  have 
resulted in a similar, but less severe, age-dependent impact on sur-
vival. Although the patients younger than age 65 lived 29 months, the 
survival time expected of the entire group, the cells lost during sipu-
leucel-T manufacture may have contributed to the 5.6-month shorter 
survival of patients older than 65 years. Such an explanation would not 
involve a therapeutic benefit related to the chimeric antigen.
The  field  of  immunosenescence  provides  support  for  this 
alternative  explanation.  The  age-dependent  deterioration  of 
multiple components of the immune system are widely accepted 
and believed to contribute to the increased incidence of cancer in 
the  elderly  (Box  1)  (40,41).  Each  of  these  affected  elements  is 
believed to be involved in the recognition and suppression of de-
veloping malignancies (42–45), and therefore a depletion of cel-
lular  elements  by  apheresis  with  inadequate  replacement  could 
exacerbate some or all of these age-related immunodeficiencies.
Because T cells are proposed to be enacting the purported 
treatment effect of sipuleucel-T, it is of particular note that the 
age-related decline in both naive and memory T-cell diversity is 
not linear, but that age 65–70 years is associated with a precipitous 
contraction (29,46). This collapse in both number and diversity 
of  circulating  naive  T-cells  is  believed  to  underlie  the  poor 
response  to  vaccination  in  elderly  humans  and  primates 
(13,14,47) and by similar mechanisms leads to a reduced ability 
to respond to new tumor antigens (14,15). Thus, there is a solid 
scientific and mechanistic basis for belief that the intervention-
related depletion could have a greater detrimental effect on the 
anticancer  immune  competence  of  older  individuals,  with  65 
years  representing  an  important  threshold  age.  Homeostatic 
proliferation and migration of peripheral T-cells might maintain 
the absolute numbers in the circulation (48); yet the resultant 
population  would  differ  from  the  unperturbed  population  in 
important functional ways (49).
Overall, we believe that a detrimental effect of the placebo inter-
vention is at least as plausible as a beneficial effect of sipuleucel-T 
as  an  explanation  of  the  survival  difference  observed  in  the 
IMPACT trial. We would be interested in other possible explana-
tions  for  the  11-month  survival  difference  between  placebo 
patients older and younger than age 65, as well as explanations for 
why the patients in whom sipuleucel-T is apparently efficacious 
(aged >65 years) live clinically and statistically significantly shorter 
lives than the patients in whom it has no apparent efficacy (aged <65 
years).  The  safety  of  prostate  cancer  patients  as  well  as  the   278   Commentary | JNCI  Vol. 104, Issue 4  | February 22,  2012
judicious  development  of  beneficial  immunotherapies  depends   
on  addressing  the  concerns  raised  and  considering  all  possible   
interpretations of the IMPACT trial results.
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